Regulation of the mTOR-Rac1 axis in platelet function

Small GTPases

Volumn 3, Issue 1, 2012, Pages

  Aslan, Joseph E ^a   McCarty, Owen J T ^a  

^a Oregon Health and Science University Department of Biomedical Engineering   (United States)

Author keywords

Actin; Cytoskeleton; GEF; P Rex1; Rac1; Rapamycin; Rheb; S6K1; TIAM1; TSC2

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTEGRIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN BCL 3; PROTEIN TYROSINE KINASE; RAC1 PROTEIN; RAC1 PROTEIN GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAPAMYCIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; S6 KINASE; S6 KINASE 1; UNCLASSIFIED DRUG; VAV PROTEIN; VAV1 PROTEIN;

ANTICOAGULATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; COMPLEX FORMATION; CYTOSKELETON; ENZYME ACTIVATION; ENZYME ACTIVITY; GRAFT REJECTION; HEMOSTASIS; PHOSPHORYLATION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

EID: 84859029508     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: 10.4161/sgtp.3.1.19137     Document Type: Article

References (34)

1. Wei AH, Schoenwaelder SM, Andrews RK, Jackson SP. New insights into the haemostatic function of platelets. Br J Haematol 2009; 147:415-430; PMID: 19656155; http://dx.doi.org/10.1111/j.1365-2141.2009.07819.x
2. Li Z, Delaney MK, O'Brien KA, Du X. Signaling during platelet adhesion and activation. Arterioscler Thromb Vasc Biol 2010; 30:2341-2349; PMID: 21071698; http://dx.doi.org/10.1161/ATVBAHA.110.207522
3. Klages B, Brandt U, Simon MI, Schultz G, Offermanns S. Activation of G12/G13 results in shape change and Rho/Rho-kinase-mediated myosin light chain phosphorylation in mouse platelets. J Cell Biol 1999; 144:745-754; PMID:10037795; http://dx.doi.org/10.1083/jcb.144.4.745
4. Schoenwaelder SM, Hughan SC, Boniface K, Fernando S, Holdsworth M, Thompson PE, et al. RhoA sustains integrin alpha IIbbeta 3 adhesion contacts under high shear. J Biol Chem 2002; 277:14738-14746; PMID: 11830597
5. Pleines I, Hagedorn I, Gupta S, May F, Chakarova L, van Hengel J, et al. Megakaryocyte-specific RhoA deficiency causes macrothrombocytopenia and defective platelet activation in hemostasis and thrombosis. Blood 2011. In press. PMID:22045984; http://dx.doi.org/10.1182/blood-2011-08-372193
6. McCarty OJ, Larson MK, Auger JM, Kalia N, Atkinson BT, Pearce AC, et al. Rac1 is essential for platelet lamellipodia formation and aggregate stability under flow. J Biol Chem 2005; 280:39474-39484; PMID:16195235; http://dx.doi.org/10.1074/jbc.M504672200
7. Pearce AC, Wilde JI, Doody GM, Best D, Inoue O, Vigorito E, et al. Vav1, but not Vav2, contributes to platelet aggregation by CRP and thrombin, but neither is required for regulation of phospholipase C. Blood 2002; 100:3561-3569; PMID:12411320; http://dx.doi.org/10.1182/blood.V100.10.3561
8. Akbar H, Shang X, Perveen R, Berryman M, Funk K, Johnson JF, et al. Gene targeting implicates Cdc42 GTPase in GPVI and non-GPVI mediated platelet filopodia formation, secretion and aggregation. PLoS One 2011; 6:e22117; PMID:21789221; http://dx.doi.org/10.1371/journal.pone.0022117
9. Watson SP, Auger JM, McCarty OJ, Pearce AC. GPVI and integrin alphaIIb beta3 signaling in platelets. J Thromb Haemost 2005; 3:1752-1762; PMID:16102042; http://dx.doi.org/10.1111/j.1538-7836.2005.01429.x
10. Zhou H, Huang S. MTOR signaling in cancer cell motility and tumor metastasis. Crit Rev Eukaryot Gene Expr 2010; 20:1-16; PMID:20528734
11. Zoncu R, Efeyan A, Sabatini DM. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011; 12:21-35; PMID:21157483; http://dx.doi.org/10.1038/nrm3025
12. Dann SG, Selvaraj A, Thomas G. MTOR Complex1-S6K1 signaling: at the crossroads of besity, diabetes and cancer. Trends Mol Med 2007; 13:252-259; PMID: 17452018; http://dx.doi.org/10.1016/j.molmed.2007.04.002
13. Wander SA, Hennessy BT, Slingerland JM. Nextgeneration mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest 2011; 121:1231-1241; PMID:21490404; http://dx.doi.org/10.1172/JCI44145
14. Rhoads JM, Niu X, Odle J, Graves LM. Role of mTOR signaling in intestinal cell migration. Am J Physiol Gastrointest Liver Physiol 2006; 291:G510-G517; PMID:16710051; http://dx.doi.org/10.1152/ajpgi.00189.2005
15. Sakakibara K, Liu B, Hollenbeck S, Kent KC. Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am J Physiol Heart Circ Physiol 2005; 288:H2861-H2868; PMID: 15708965; http://dx.doi.org/10.1152/ajpheart.00561.2004
16. Ip CK, Cheung AN, Ngan HY, Wong AS. P70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 2011; 30:2420-2432; PMID:21258406; http://dx.doi.org/10.1038/onc.2010.615
17. Gulhati P, Bowen KA, Liu J, Stevens PD, Rychahou PG, Chen M, et al. MTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res 2011; 71:3246-3256; PMID:21430067; http://dx.doi.org/10.1158/0008-5472.CAN-10-4058
18. Chou MM, Blenis J. The 70 kDa S6 kinase complexes with and is activated by the Rho family G proteins Cdc42 and Rac1. Cell 1996; 85:573-583; PMID: 8653792; http://dx.doi.org/10.1016/S0092-8674(00)81257-X
19. Crouch MF. Regulation of thrombin-induced stress fibre formation in Swiss 3T3 cells by the 70-kDa S6 kinase. Biochem Biophys Res Commun 1997; 233: 193-199; PMID:9144421; http://dx.doi.org/10.1006/bbrc.1997.6419
20. Weyrich AS, Denis MM, Schwertz H, Tolley ND, Foulks J, Spencer E, et al. MTOR-dependent synthesis of Bcl-3 controls the retraction of fibrin clots by activated human platelets. Blood 2007; 109:1975-1983; PMID:17110454; http://dx.doi.org/10.1182/blood-2006-08-042192
21. Weyrich AS, Dixon DA, Pabla R, Elstad MR, McIntyre TM, Prescott SM, et al. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc Natl Acad Sci U S A 1998; 95:5556-5561; PMID:9576921; http://dx.doi.org/10.1073/pnas.95.10.5556
22. Pan CJ, Tang JJ, Weng YJ, Wang J, Huang N. Preparation and characterization of rapamycin-loaded PLGA coating stent. J Mater Sci Mater Med 2007; 18:2193-2198; PMID:17607513; http://dx.doi.org/10.1007/s10856-007-3075-9
23. Aslan JE, Tormoen GW, Loren CP, Pang J, McCarty OJ. S6K1 and mTOR regulate Rac1-driven platelet activation and aggregation. Blood 2011; 118:3129-3136; PMID:21757621; http://dx.doi.org/10.1182/blood-2011-02-331579
24. Rosenwald IB, Pechet L, Han A, Lu L, Pihan G, Woda B, et al. Expression of translation initiation factors elF-4E and elF-2alpha and a potential physiologic role of continuous protein synthesis in human platelets. Thromb Haemost 2001; 85:142-151; PMID:11204566
25. Buchsbaum RJ, Connolly BA, Feig LA. Regulation of p70 S6 kinase by complex formation between the Rac guanine nucleotide exchange factor (Rac-GEF) Tiam1 and the scaffold spinophilin. J Biol Chem 2003; 278:18833-18841; PMID:12531897; http://dx.doi.org/10.1074/jbc.M207876200
26. Hernández-Negrete I, Carretero-Ortega J, Rosenfeldt H, Hernández-García R, Calderón-Salinas JV, Reyes-Cruz G, et al. P-Rex1 links mammalian target of rapamycin signaling to Rac activation and cell migration. J Biol Chem 2007; 282:23708-23715; PMID:17565979; http://dx.doi.org/10.1074/jbc.M703771200
27. Sosa MS, Lopez-Haber C, Yang C, Wang H, Lemmon MA, Busillo JM, et al. Identification of the Rac-GEF PRex1 as an essential mediator of ErbB signaling in breast cancer. Mol Cell 2010; 40:877-892; PMID: 21172654; http://dx.doi.org/10.1016/j.molcel.2010.11.029
28. Welch HC, Coadwell WJ, Ellson CD, Ferguson GJ, Andrews SR, Erdjument-Bromage H, et al. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guaninenucleotide exchange factor for Rac. Cell 2002; 108:809-821; PMID:11955434; http://dx.doi.org/10.1016/S0092-8674(02)00663-3
29. Aslan JE, Spencer AM, Loren CP, Pang J, Welch HC, Greenberg DL, et al. Characterization of the Rac guanine nucleotide exchange factor P-Rex1 in platelets. J Mol Signal 2011; 6:11; PMID:21884615; http://dx.doi.org/10.1186/1750-2187-6-11
30. Saci A, Cantley LC, Carpenter CL. Rac1 regulates the activity of mTORC1 and mTORC2 and controls cellular size. Mol Cell 2011; 42:50-61; PMID: 21474067; http://dx.doi.org/10.1016/j.molcel.2011.03.017
31. Guertin DA, Sabatini DM. The pharmacology of mTOR inhibition. Sci Signal 2009; 2:pe24; PMID: 19383975; http://dx.doi.org/10.1126/scisignal.267pe24
32. Moore SF, Hunter RW, Hers I. MTORC2 protein complex-mediated Akt (Protein Kinase B) Serine 473 Phosphorylation is not required for Akt1 activity in human platelets [corrected]. J Biol Chem 2011; 286:24553-24560; PMID:21592956; http://dx.doi.org/10.1074/jbc.M110.202341
33. Liu L, Das S, Losert W, Parent CA. MTORC2 regulates neutrophil chemotaxis in a cAMP- and RhoA-dependent fashion. Dev Cell 2010; 19:845-857; PMID:21145500; http://dx.doi.org/10.1016/j.devcel.2010.11.004
34. Huang J, Manning BD. A complex interplay between Akt, TSC2 and the two mTOR complexes. Biochem Soc Trans 2009; 37:217-222; PMID:19143635; http://dx.doi.org/10.1042/BST0370217